Sign in
Taking people in United StatesNo phase

Comparing two surgical methods for removing the bladder in men with bladder cancer

Compares two bladder removal surgeries in men with bladder cancer, one sparing the prostate capsule.

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore and Washington D.C., United StatesSee the 2 sites
Trial code
Registry title
Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
Status
Recruiting
People taking part
70 people, planned
Started
25 Oct 2023
Expected to end
Jul 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Prostate capsule-sparing radical cystectomy
  • Nerve sparing radical cystectomy
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with confirmed bladder cancer who are scheduled for radical cystectomy (bladder removal surgery). It compares two types of the operation.

Age
Older than 18 years
Sex
Men only
Disease stage
Confirmed bladder cancer, scheduled for radical cystectomy. Variant histologies of bladder cancer are allowed. Cancer in the bladder neck or prostate, including the prostatic urethra, is not allowed.
Earlier treatment
Neoadjuvant therapy is allowed. Prior pelvic radiation is not allowed.

Main reasons for not taking part

  • Not a candidate for cystectomy
  • Moderate to severe erectile dysfunction (SHIM score <17)
  • Bladder cancer involving the bladder neck or prostate, including the prostatic urethra
  • Prior pelvic radiation
  • Confirmed prostate cancer, or increased genetic risk of prostate cancer, or Lynch syndrome

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Subjects with pathologically confirmed bladder cancer scheduled for radical cystectomy
  • Variant histologies of bladder cancer permitted
  • Neoadjuvant therapy permitted
  • Age > 18 years old
  • Ability to understand and willingness to sign a written informed consent document

Who cannot take part

  • Prior pelvic radiation
  • Bladder cancer with bladder neck or prostatic involvement, including cancer in the prostatic urethra
  • Confirmed prostate cancer:
  • Patients with abnormal Digital rectal exam (DRE), PSA >3 or Prostate Imaging Reporting \& Data System (PIRADS) 4 lesions on prostate Multiparametric MRI (mpMRI) will undergo prostate biopsy to rule out prostate cancer
  • Increased genetic risk of prostate cancer per National Comprehensive Cancer Network (NCCN) guidelines:
  • ≥3 first- or second-degree relatives with: Lynch syndrome-related cancers, especially if diagnosed
  • Patients with Lynch syndrome
  • ≥1 first-, second-, or third-degree relative with: breast cancer at age ≤50 y, colorectal or endometrial cancer at age ≤50 y, male breast cancer at any age, ovarian cancer at any age, exocrine pancreatic cancer at any age, metastatic, regional, very-high-risk, high-risk prostate cancer at any age
  • ≥1 first-degree relative (father or brother) with: prostate cancer at age ≤60 y
  • ≥2 first-, second-, or third-degree relatives with: breast cancer at any age, prostate cancer at any age
  • Patients that are not candidates for cystectomy
  • Moderate to severe erectile dysfunction with SHIM score <17

Where in United States

  • Johns Hopkins HospitalBaltimore, United StatesContact: Armine Smith, MDTaking people
  • Sibley Memorial HospitalWashington D.C., United StatesContact: Armine Smith, MDTaking people

About the trial

What the trial wants to find out

The purpose of this clinical trial is to determine if prostate-capsule-sparing cystectomy improves functional outcomes without comprising oncologic outcomes in male patients receiving a radical cystectomy. Patients will be randomized to one of two groups: prostate capsule-sparing radical cystectomy or nerve-sparing radical cystectomy. Patients will be monitored following standard of care guidelines and clinical data will be collected. Patients in both groups will be asked to complete an erectile function questionnaire at multiple timepoints. Patients who receive an orthotopic neobladder will be asked to complete a questionnaire to monitor urinary function at multiple timepoints. Patient adverse events will be monitored to ensure patients safety.

The 2 groups in the trial

  • Prostate Capsule-Sparing Radical CystectomyOther group

    Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.

  • Nerve-Sparing Radical CystectomyOther group

    Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective, Randomized Trial Comparing Prostate Capsule-sparing and Nerve-sparing Radical Cystectomy in Patients With Bladder Cancer
Plain-language title
Comparing two surgical methods for removing the bladder in men with bladder cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026